- Home
- FGMC vs IGMS Comparison
FGMC vs IGMS Comparison
Compare FGMC & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGMC
- IGMS
- Stock Information
- Founded
- FGMC 2023
- IGMS 1993
- Country
- FGMC United States
- IGMS United States
- Employees
- FGMC N/A
- IGMS N/A
- Industry
- FGMC
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- FGMC
- IGMS Health Care
- Exchange
- FGMC NYSE
- IGMS Nasdaq
- Market Cap
- FGMC 98.9M
- IGMS 82.1M
- IPO Year
- FGMC 2025
- IGMS 2019
- Fundamental
- Price
- FGMC $9.78
- IGMS $1.25
- Analyst Decision
- FGMC
- IGMS Hold
- Analyst Count
- FGMC 0
- IGMS 8
- Target Price
- FGMC N/A
- IGMS $6.14
- AVG Volume (30 Days)
- FGMC 30.4K
- IGMS 173.6K
- Earning Date
- FGMC 01-01-0001
- IGMS 05-13-2025
- Dividend Yield
- FGMC N/A
- IGMS N/A
- EPS Growth
- FGMC N/A
- IGMS N/A
- EPS
- FGMC 0.08
- IGMS N/A
- Revenue
- FGMC N/A
- IGMS $2,681,000.00
- Revenue This Year
- FGMC N/A
- IGMS $124.45
- Revenue Next Year
- FGMC N/A
- IGMS $45.07
- P/E Ratio
- FGMC $566.65
- IGMS N/A
- Revenue Growth
- FGMC N/A
- IGMS 27.36
- 52 Week Low
- FGMC $9.53
- IGMS $0.92
- 52 Week High
- FGMC $9.85
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- FGMC N/A
- IGMS 55.17
- Support Level
- FGMC N/A
- IGMS $1.13
- Resistance Level
- FGMC N/A
- IGMS $1.42
- Average True Range (ATR)
- FGMC 0.00
- IGMS 0.09
- MACD
- FGMC 0.00
- IGMS 0.02
- Stochastic Oscillator
- FGMC 0.00
- IGMS 64.71
About FGMC FG MERGER II CORP
FG Merger II Corp is a blank check company, incorporated for the purpose of merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities (Business Combination).
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.